Rhumbline Advisers Has $5.41 Million Stake in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Rhumbline Advisers has decreased its position in Supernus Pharmaceuticals by 4.1%, selling 7,121 shares, and now owns 165,323 shares valued at approximately $5.4 million.
• Several other large investors have increased their holdings in Supernus, with Armistice Capital LLC growing its stake by 7.4%, and GW&K Investment Management LLC by 14.6% during the same quarter.
• Analysts have revised their ratings and price targets for Supernus Pharmaceuticals, with Piper Sandler raising their target from $36 to $40, indicating a trend toward more positive sentiment among market analysts.

Rhumbline Advisers decreased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 4.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 165,323 shares of the specialty pharmaceutical company's stock after selling 7,121 shares during the period. Rhumbline Advisers owned approximately 0.30% of Supernus Pharmaceuticals worth $5,414,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Raiffeisen Bank International AG acquired a new position in Supernus Pharmaceuticals in the 4th quarter worth $25,000. Financial Management Professionals Inc. bought a new position in shares of Supernus Pharmaceuticals during the first quarter worth about $30,000. Versant Capital Management Inc grew its holdings in shares of Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock worth $37,000 after buying an additional 1,109 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Supernus Pharmaceuticals in the 4th quarter valued at approximately $42,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Supernus Pharmaceuticals in the first quarter worth $41,000.

Insider Activity at Supernus Pharmaceuticals

In related news, Director Bethany Sensenig sold 5,369 shares of the firm's stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $42.25, for a total transaction of $226,840.25. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Frederick M. Hudson sold 7,457 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $42.26, for a total value of $315,132.82. Following the completion of the transaction, the director owned 46,307 shares of the company's stock, valued at $1,956,933.82. This represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 246,506 shares of company stock valued at $10,696,144. 8.80% of the stock is owned by company insiders.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock traded down $1.47 during trading on Monday, reaching $43.99. 794,454 shares of the company's stock were exchanged, compared to its average volume of 595,633. The firm's 50-day moving average price is $39.67 and its 200 day moving average price is $34.70. The company has a market cap of $2.47 billion, a P/E ratio of 38.25 and a beta of 0.79. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $46.78.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SUPN. Cantor Fitzgerald raised their price target on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research note on Wednesday, August 6th. Piper Sandler upped their target price on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a research report on Friday, August 29th. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Finally, Zacks Research raised Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, Supernus Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $43.00.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.